SV2018005693A - Enlazadores de ctla4 - Google Patents

Enlazadores de ctla4

Info

Publication number
SV2018005693A
SV2018005693A SV2018005693A SV2018005693A SV2018005693A SV 2018005693 A SV2018005693 A SV 2018005693A SV 2018005693 A SV2018005693 A SV 2018005693A SV 2018005693 A SV2018005693 A SV 2018005693A SV 2018005693 A SV2018005693 A SV 2018005693A
Authority
SV
El Salvador
Prior art keywords
molecules
ctla4
ctla4 binders
treat
nanocbodies
Prior art date
Application number
SV2018005693A
Other languages
English (en)
Spanish (es)
Inventor
Juha Punnonen
Maribel Beaumont
Marie -Ange Buyse
Carlo Boutton
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SV2018005693A publication Critical patent/SV2018005693A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SV2018005693A 2015-11-18 2018-05-15 Enlazadores de ctla4 SV2018005693A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562257001P 2015-11-18 2015-11-18

Publications (1)

Publication Number Publication Date
SV2018005693A true SV2018005693A (es) 2019-01-18

Family

ID=57472066

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005693A SV2018005693A (es) 2015-11-18 2018-05-15 Enlazadores de ctla4

Country Status (30)

Country Link
US (2) US10501542B2 (ko)
EP (1) EP3377527A1 (ko)
JP (1) JP6768800B2 (ko)
KR (1) KR102095140B1 (ko)
CN (1) CN108473565B (ko)
AR (1) AR106753A1 (ko)
AU (1) AU2016355569B2 (ko)
BR (1) BR112018009972B1 (ko)
CA (1) CA3004900C (ko)
CL (1) CL2018001326A1 (ko)
CO (1) CO2018005161A2 (ko)
CR (1) CR20180279A (ko)
DO (1) DOP2018000125A (ko)
EA (1) EA038179B1 (ko)
EC (1) ECSP18045497A (ko)
GE (1) GEP20207174B (ko)
HK (1) HK1254952A1 (ko)
IL (1) IL259173A (ko)
JO (1) JO3739B1 (ko)
MA (1) MA43259A (ko)
MX (1) MX2018006246A (ko)
MY (1) MY189590A (ko)
NI (1) NI201800062A (ko)
PH (1) PH12018501079A1 (ko)
SG (1) SG11201804127SA (ko)
SV (1) SV2018005693A (ko)
TN (1) TN2018000169A1 (ko)
TW (1) TWI754622B (ko)
UA (1) UA125337C2 (ko)
WO (1) WO2017087588A1 (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
IN2014CN00373A (ko) 2011-06-23 2015-04-03 Ablynx Nv
KR20170002645A (ko) 2014-05-16 2017-01-06 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
AU2016355569B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc CTLA4 binders
UA121914C2 (uk) 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Молекула, що зв'язує pd1 і lag3
AU2016357460B2 (en) * 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
CA3026477A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
US11673954B2 (en) * 2017-11-17 2023-06-13 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-L1
US20230167177A1 (en) * 2018-03-19 2023-06-01 WuXi Biologics Ireland Limited Novel anti-ctla-4 antibody polypeptide
JP2022502403A (ja) 2018-09-26 2022-01-11 アセンディス ファーマ エー／エス 分解性ヒアルロン酸ヒドロゲル
JP2022514702A (ja) 2018-12-21 2022-02-14 オーエスイー・イミュノセラピューティクス 二機能性抗ｐｄ－１／ｉｌ－７分子
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN110950957B (zh) * 2019-12-13 2022-03-08 源道隆（苏州）医学科技有限公司 可结合ctla4的多肽及其应用
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
CN115626956A (zh) * 2020-01-16 2023-01-20 三优生物医药(上海)有限公司 Ctla-4结合分子及其用途
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
EP4281187A1 (en) * 2021-01-20 2023-11-29 Bioentre LLC Ctla4-binding proteins and methods of treating cancer
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
IL307419A (en) 2021-04-09 2023-12-01 Ose Immunotherapeutics A new scaffold for bifunctional molecules with improved properties
WO2023163968A1 (en) * 2022-02-24 2023-08-31 Merck Sharp & Dohme Llc Stable formulations of a multivalent vhh based cytotoxic t lymphocyte associated antigen 4 (ctla4) binder binding to human ctla4 and methods of use thereof
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
JP3444885B2 (ja) 1992-08-21 2003-09-08 フリーイェ・ユニヴェルシテイト・ブリュッセル Ｌ鎖欠落免疫グロブリン
WO1994008007A1 (en) 1992-09-29 1994-04-14 President And Fellows Of Harvard College Trophic factor having ion channel-inducing activity in neuronal cells
US6824779B1 (en) 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
EP2264166B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US20020006403A1 (en) 1999-12-14 2002-01-17 Xue-Zhong Yu CD28-specific antibody compositions for use in methods of immunosuppression
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
ES2367891T3 (es) 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JP4066166B2 (ja) 2000-12-26 2008-03-26 アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） 抗−ｃｄ２８抗体
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
MXPA05004955A (es) 2002-11-08 2005-11-17 Ablynx Nv Anticuerpos de region unica dirigidos contra el factor-alfa de necrosis de tumor y usos de estos.
AU2004204262B2 (en) 2003-01-10 2010-11-04 Ablynx N.V. Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
ES2352697T3 (es) 2003-11-07 2011-02-22 Ablynx N.V. Anticuerpos de dominio único de camelidae vhh dirigidos contra el receptor del factor de crecimiento epidérmico y usos de los mismos.
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
EP1863847A2 (en) 2004-12-02 2007-12-12 Domantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
JP5047950B2 (ja) 2005-05-18 2012-10-10 アブリンクス エン．ヴェー． 腫瘍壊死因子−アルファに対する改良ナノボディ（商標）
ES2852423T3 (es) 2005-05-20 2021-09-13 Ablynx Nv NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
JP2009519011A (ja) 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
TW200736276A (en) 2005-12-01 2007-10-01 Domantis Ltd Competitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
EP1976991A1 (en) 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
JP2010511397A (ja) 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． 血清タンパク質と結合可能なペプチド
WO2008071447A2 (en) * 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
KR101264473B1 (ko) 2007-05-24 2013-05-29 아블린쓰 엔.브이. Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
PT2207809E (pt) 2007-09-26 2013-10-09 Amgen Inc Proteínas de ligação a antigénio de factor de crescimento do tipo factor de crescimento epidérmico de ligação de heparina
AU2008328781A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
JP2012507260A (ja) * 2008-07-18 2012-03-29 ドマンティス リミテッド Ｃｄ２８結合のための一価の組成物及び使用方法
CN102574914A (zh) 2009-07-16 2012-07-11 葛兰素集团有限公司 改进的抗血清清蛋白结合性单可变区
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
LT2723771T (lt) 2011-06-23 2019-12-10 Ablynx Nv Serumo albuminą surišantys baltymai
IN2014CN00373A (ko) 2011-06-23 2015-04-03 Ablynx Nv
BR112014003679B1 (pt) 2011-08-17 2022-08-30 Glaxo Group Limited Domínio variável de imunoglobulina único, composição farmacêutica, formulação, ácido nucleico isolado ou recombinante, vetor, microorganismo transgênico, e, uso de uma composição farmacêutica
WO2013066765A1 (en) 2011-11-01 2013-05-10 Merck Sharp & Dohme Corp. Mutation of tup1 in glycoengineered yeast
WO2014043509A2 (en) 2012-09-13 2014-03-20 Novartis Ag Antigen binding molecule with terminal modifications
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
CN115160441A (zh) * 2013-09-26 2022-10-11 埃博灵克斯股份有限公司 双特异性纳米抗体
KR20170002645A (ko) 2014-05-16 2017-01-06 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
RU2755724C2 (ru) 2015-11-18 2021-09-20 Мерк Шарп И Доум Корп. Pd1/ctla4-связывающие вещества
AU2016355569B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc CTLA4 binders
UA121914C2 (uk) 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Молекула, що зв'язує pd1 і lag3
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法

Also Published As

Publication number Publication date
MX2018006246A (es) 2018-08-01
MY189590A (en) 2022-02-18
GEP20207174B (en) 2020-11-10
MA43259A (fr) 2018-09-26
CR20180279A (es) 2018-08-24
EA038179B1 (ru) 2021-07-20
PH12018501079A1 (en) 2019-01-28
GEAP201614811A (ko) 2020-07-10
CA3004900C (en) 2021-08-10
AU2016355569A1 (en) 2018-05-17
NI201800062A (es) 2018-07-24
EP3377527A1 (en) 2018-09-26
US20170137521A1 (en) 2017-05-18
US10501542B2 (en) 2019-12-10
SG11201804127SA (en) 2018-06-28
CN108473565A (zh) 2018-08-31
EA201891166A1 (ru) 2018-11-30
HK1254952A1 (zh) 2019-08-02
IL259173A (en) 2018-06-28
US11649290B2 (en) 2023-05-16
JP2019503655A (ja) 2019-02-14
TW201726741A (zh) 2017-08-01
TN2018000169A1 (en) 2019-10-04
BR112018009972A2 (pt) 2018-11-13
TWI754622B (zh) 2022-02-11
KR102095140B1 (ko) 2020-03-31
US20200157220A1 (en) 2020-05-21
KR20180070712A (ko) 2018-06-26
CA3004900A1 (en) 2017-05-26
CL2018001326A1 (es) 2018-10-12
ECSP18045497A (es) 2018-07-31
DOP2018000125A (es) 2018-09-30
AU2016355569B2 (en) 2020-01-02
BR112018009972B1 (pt) 2021-08-24
AR106753A1 (es) 2018-02-14
WO2017087588A1 (en) 2017-05-26
CN108473565B (zh) 2022-05-27
CO2018005161A2 (es) 2018-11-30
JO3739B1 (ar) 2021-01-31
JP6768800B2 (ja) 2020-10-14
UA125337C2 (uk) 2022-02-23

Similar Documents

Publication Publication Date Title
SV2018005693A (es) Enlazadores de ctla4
SV2018005694A (es) Enlazadores de pd1 y/o lag3
GT201700033A (es) Anticuerpos anti tigit
GT201700112A (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
ECSP19020740A (es) Anticuerpos anti-cd27
GT201700286A (es) Modulación y tratamiento inmunes de tumores sólidos con anticuerpos que se unen específicamente a cd38
CL2017002752A1 (es) Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
DOP2016000224A (es) Tratamientos combinados con anticuerpos anti-cd38
UY35965A (es) Anticuerpos humanos contra pd?l1
UY35399A (es) Conjugados de fármacos con anticuerpos
BR112016022841A2 (pt) cadeia j modificada
CR20160347A (es) Moléculas de anticuerpo que se unen a tim-3 y usos de las mismas
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
EA201792058A1 (ru) Виротерапия комбинацией антител
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
DK3277325T3 (da) Kombinationsimmunterapi for cancer
AR120118A2 (es) Anticuerpos anti tigit